Braxia Scientific Corp. is a medical research company, which engages in owning and operating multidisciplinary clinics and providing treatment for mental health disorders. The firm is also involved in research activities related to discovering and commercializing novel drugs and delivery methods. It develops ketamine and derivatives and other psychedelic products from its IP development platform. It operates under the Canada and U.S. geographical segments. The company was founded on March 26, 2019 and is headquartered in Toronto, Canada.